Day: June 14, 2021

SAN DIEGO, June 14, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, and James Levine, Chief Financial Officer, will participate in investor meetings at the Raymond James Human Health Innovation Conference, being held virtually June 21-23, 2021. About Cidara TherapeuticsCidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to AVCs for the prevention and treatment of influenza and other viral...

CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held June 16-17, 2021. During the fireside chat, Cue Biopharma will provide an update highlighting the ongoing Phase 1a/1b monotherapy dose escalation clinical trial of CUE-101, as second-line treatment for patients with HPV+ recurrent/metastatic head and neck cancer. The discussion will include details pertaining to cohort 6 of the dose escalation Part A and the recently announced initiation of the patient expansion Part B at the recommended Phase...

FLORHAM PARK, N.J., June 14, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage cancer immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced it will host an Oncology R&D Day for analysts, investors, and the scientific community on Wednesday, June 16th. The research and development day is scheduled to begin at 8:00 am ET on Wednesday, June 16th, 2021. Participants should dial 877-407-3088 (United States) or 201-389-0927 (International) and mention PDS Biotechnology. PDS Biotech’s Oncology R&D Day will focus on the Company’s advancements in its ongoing preclinical and clinical work and will feature presentations from:Dr. Frank Bedu-Addo, President and CEO, PDS Biotech Dr. Lauren V. Wood, Chief...

VANCOUVER, British Columbia, June 14, 2021 (GLOBE NEWSWIRE) — Trailbreaker Resources Ltd. (TBK.V) (“Trailbreaker” or “the Company”) is pleased to announce the mobilization of its exploration team to its 100%-owned Atsutla Gold project, located in northwestern British Columbia (BC). This Phase 1 program will involve reconnaissance and detailed geochemical soil sampling, prospecting, and geological mapping at both the Willie Jack and Swan properties which comprise the Atsutla Gold project. The Company intends to thoroughly follow-up on the high-grade discoveries made at Willie Jack in 2020 as well as explore newly staked ground. In addition to this, the team will re-examine the historic exploration and drilling done at the Swan property, with a renewed focus on gold mineralization. The Atsutla Gold project covers over 23,000 hectares...

NASHVILLE, Tenn., June 14, 2021 (GLOBE NEWSWIRE) — Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced that it has commenced an underwritten registered public offering of $17.5 million aggregate principal amount of its 8.625% senior notes due 2026 (the “Notes”), subject to market and certain other conditions. The Notes will be treated as a single series with the Company’s outstanding 8.625% senior notes due 2026 and will trade interchangeably with the existing notes. The Company expects to grant the underwriters a 30-day option to purchase additional senior notes in connection with the offering. Harrow Health and this issuance of Notes both received a rating of “BB” from Egan-Jones Ratings Company, an independent, unaffiliated rating agency. The Company...

LexaGene to Present at Multiple Conferences BEVERLY, Mass., June 14, 2021 (GLOBE NEWSWIRE) — LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG), a molecular diagnostics company, announced the Company has sold another MiQLab™ System and the CEO will present at multiple conferences. LexaGene CEO and Founder, Dr. Jack Regan, states, “Following up on last weeks’ sales news, I’m pleased to report we have sold another MiQLab System. We will be shipping this purchased system to Alpine Veterinary Hospital in Concord, California. Alpine Veterinary Hospital, led by Dr. Virk, provides a wide range of services including emergency and orthopedic surgeries in the Bay Area of California. Dr. Virk is a passionate proponent of antimicrobial stewardship and is committed to providing the best animal care through diagnostics. He believes the MiQLab...

TORONTO, June 14, 2021 (GLOBE NEWSWIRE) — Further to its news release dated May 12, 2021, RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or “RAMM“) (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical and other cannabis-based products, together with Canapar Corp. (“Canapar”), are pleased to announce that, at the special meeting of shareholders of Canapar (the “Canapar Shareholders“), the Canapar Shareholders overwhelmingly voted in favour of the special resolution to approve the amalgamation of Canapar and a wholly-owned subsidiary of RAMM (the “Amalgamation”), pursuant to which RAMM will acquire all of the common shares of Canapar not otherwise owned by the Company. The Amalgamation was approved by approximately 98% of votes cast by the Canapar Shareholders. Completion...

TORONTO, June 14, 2021 (GLOBE NEWSWIRE) — YAMANA GOLD INC. (TSX: YRI; NYSE: AUY; LSE: AUY) (“Yamana” or “the Company”) is pleased to announce that it has agreed to acquire from Globex Mining Enterprises Inc. the Francoeur, Arntfield and Lac Fortune gold properties adjoining the Company’s Wasamac project as well as additional claims in the Beuchastel township to the east of the Wasamac project. The acquisition of the Globex claims will significantly add to the exploration upside of the Wasamac project, and it is consistent with Yamana’s strategy to expand its presence in the Abitibi-Témiscamingue Region of Quebec. Historical drilling, previous production from Francoeur and Arntfield, both former operating mines, and recent trenching and exploration work by Globex has defined a six-kilometre western continuation of the Wasa shear...

CHICAGO, June 14, 2021 (GLOBE NEWSWIRE) — GCM Grosvenor (Nasdaq: GCMG), a global alternative asset management solutions provider, announced today that it will seek to upsize its Term Loan by $85 million to enable the repurchase of certain fund investments and rights to future carry associated with Mosaic (collectively, the “Mosaic Assets”). Based upon values as of March 31, 20211, GCM Grosvenor will repurchase assets and carried interest at net asset value of approximately $238 million (consisting of fund investments valued at $87 million and unrealized carried interests net asset value of $150 million) and rights to additional future carried interest associated with $423 million of carry dollars at work, for an estimated March 31, 2021 purchase price of $176 million (the “Transaction”). The Mosaic Assets generated realized carried...